How Leucocyte Cell Membrane Modified Janus Microcapsules are Phagocytosed by Cancer Cells

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cell Biology

Background:

• Current drug delivery systems struggle with complex tumors due to single-surface recognition or hydrophobicity-based methods.
• Tumor heterogeneity, including diverse surface mutations, poses a significant challenge for targeted therapies.

Purpose of the Study:

• To develop novel Janus capsules for discriminating between healthy and cancer cells.
• To overcome the limitations of existing drug delivery systems in targeting heterogeneous tumors.

Main Methods:

• Fabrication of Janus capsules using polyelectrolyte multilayer microcapsules.
• Coating Janus capsules with human leucocyte (THP-1 cell line) cell membranes.
• Testing the adhesion and interaction of modified Janus capsules with HUVEC cells and three different cancer cell lines.

Main Results:

• Modified Janus capsules successfully adhered to cancer cells.
• The capsules demonstrated discrimination between HUVEC cells and cancer cell lines.
• Leucocyte cell-membrane-coated Janus capsules were phagocytosed, with the membrane facing the cells, despite compromising leucocyte integrity.

Conclusions:

• Janus capsules functionalized with cell membranes offer a promising approach for targeted cancer therapy.
• This method provides a new strategy for drug delivery systems to overcome tumor heterogeneity.
• The observed phagocytosis mechanism suggests potential for intracellular drug delivery.